MarketPeel
Insider Trading Intelligence
DP

Daniel R. Passeri

CUE
CHIEF EXECUTIVE OFFICER · CUE BIOPHARMA, INC. · CIK 0001190121
FILING MIX · LIFETIME72%/28%
BUYS
13
SELLS
5
TOTAL VALUE
$707.8K
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
450,000
AVG SELL PX
$9.69
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Daniel R. Passeri, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+66.67%+0.15%-1.93%+2.08%+2.94%
14d3+0.00%-6.69%-1.76%-4.92%-7.95%
30d3+33.33%-0.58%+0.09%-0.68%-13.32%
60d3+33.33%+3.55%+0.97%+2.58%-7.67%
90d3+0.00%-14.41%-0.42%-13.99%-20.59%
180d3+33.33%+527.50%+4.12%+523.38%-36.80%
1y3+33.33%+314.94%+6.46%+308.47%-65.87%
2y3(1 pending)+50.00%+303.45%+23.86%+279.60%+279.60%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CUE · 450,000 shares · as of Mar 21, 2025
0112,500225,000337,500450,00020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
FLOW · 13 buys / 5 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
450,000450,000Mar 21, 2025Mar 25, 2025View →
CUE
CUE BIOPHARMA, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
30,000$1.03$30.9K164,578Dec 16, 2024Dec 18, 2024View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
400,000400,000Mar 6, 2024Mar 8, 2024View →
CUE
CUE BIOPHARMA, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
3,000$2.86$8.6K134,578Aug 14, 2023Aug 16, 2023View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
450,000450,000Jul 21, 2023Jul 25, 2023View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
324,000324,000Feb 16, 2023Feb 21, 2023View →
CUE
CUE BIOPHARMA, INC.
SALE
CHIEF EXECUTIVE OFFICER
75,0000Mar 31, 2022Apr 4, 2022View →
CUE
CUE BIOPHARMA, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
75,000173,700Mar 31, 2022Apr 4, 2022View →
CUE
CUE BIOPHARMA, INC.
SALE
CHIEF EXECUTIVE OFFICER
32,122$4.88$156.8K141,578Mar 31, 2022Apr 4, 2022View →
CUE
CUE BIOPHARMA, INC.
SALEGRANT
Gift
10,000131,578Mar 31, 2022Apr 4, 2022View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
100,000100,000Mar 25, 2022Mar 29, 2022View →
CUE
CUE BIOPHARMA, INC.
SALE
CHIEF EXECUTIVE OFFICER
75,00075,000Sep 30, 2021Oct 8, 2021View →
CUE
CUE BIOPHARMA, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
75,000130,377Sep 30, 2021Oct 8, 2021View →
CUE
CUE BIOPHARMA, INC.
SALE
CHIEF EXECUTIVE OFFICER
31,677$14.57$461.5K98,700Sep 30, 2021Oct 8, 2021View →
CUE
CUE BIOPHARMA, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
3,400$14.72$50.1K55,377Sep 24, 2021Sep 27, 2021View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
85,00085,000Feb 10, 2021Feb 12, 2021View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
150,000150,000Feb 5, 2020Feb 12, 2020View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
150,000150,000Feb 5, 2020Feb 12, 2020View →
Other insiders · CUE
Loading peer insiders…
About this filer
CIK 0001190121
ROLE
CHIEF EXECUTIVE OFFICER
PRIMARY
CUE
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001190121DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback